



Structured Products

Indicative pricing as at 29 May 2020

Name	IRESS Code	Date	Bid	Offer	Final Maturity Date
UBS, GOALS - Series 386	UBSGOALS386.IF	29-May-20	0.668	0.742	29-May-20

Global Sales and Trading Disclaimer

This material has been issued by UBS AG and/or any of its affiliates ("UBS" and "we", "us"). The securities, derivatives or other financial instruments described herein ("Instruments") may not be eligible for sale in all jurisdictions or to certain categories of investors. This material is for distribution only under such circumstances as may be permitted by applicable law, rules and/or regulations. All communications between you and us may be monitored. Please see further details as set out under "Country-specific information" below.

Provenance and purpose

This material has been prepared by sales or trading personnel and it is not a product of our Research Department and is not intended to recommend, suggest or inform an investment strategy. Opinions expressed may differ from the opinions expressed by our other divisions, including those of the Research Department.

Indicative Prices

The price quotations shown in this material are indicative only and show preliminary estimates of the price at which we would purchase (bid) or sell (offer) the Instruments as at a particular date and time, usually the date and time of publication (commonly referred to as "indicative price quotations"). Any such indicative price quotations are subject to change without notice at our sole discretion and should not be used for valuation or related purposes.

These indicative price quotations are provided in good faith using our standard methodology for quotations of this kind. That methodology relies on proprietary models, empirical data and assumptions that we believe to be accurate and reasonable. However, we make no representation as to the accuracy, completeness or appropriateness of such methodology.

These indicative price quotations should not be taken to suggest that any transactions have or will take place at these prices and do not constitute firm or binding offers to purchase or sell the Instruments at a certain price. They will not reflect any changes to market values or prices since the time at which they were prepared. In addition, they may not reflect adjustments for fees or as a result of the impact of our funding spreads or other internal charges.

Recipient to exercise own judgement

The information contained herein should not be regarded by recipients as a substitute for the exercise of their own judgment. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient and does not constitute the provision of investment advice. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisers to the extent you deem necessary to make your own investment, hedging and trading decisions.

Not an offer to transact

This material has been prepared for informational purposes only and is not an offer to buy or sell or a solicitation of an offer to buy or sell any Instrument or to participate in any particular trading strategy. This material is not an official confirmation of terms.

Conflicts of interest

This material may contain proprietary commentary produced in conjunction with our trading desks that trade as principal in the Instruments. This commentary may therefore not be independent from our proprietary interests or those of connected parties which may conflict with your interests. We may have accumulated or may acquire a long or short position in the subject Instrument, or derivative thereof, on the basis of this material prior to its dissemination.

We may trade as principal or otherwise act or have acted as market-maker and/or as an execution venue in the Instruments. Instruments may be highly illiquid which may adversely impact the price, spread and speed of execution of orders in those Instruments. Furthermore, we may have or have had a relationship with or may provide or have provided investment banking, capital markets and/or other financial services to the companies associated with the Instruments.

We have policies and procedures designed to manage conflicts of interest. In order to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS, we may rely on information barriers. Additional information can be found at "<https://www.ubs.com/global/en/investment-bank/regulatory.html>" and may be made available upon request.

Contents of material

This material is prepared from information believed to be reliable, but we make no representations or warranties, express or implied, and owe no duties (including in negligence) as to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the Instruments, markets or developments referred to in the materials. The information contained in this material is as of the date hereof only and is subject to change without notice. We do not undertake any obligation to update this material. Any prices or quotations contained herein are indicative only and are not for valuation purposes. Past performance is not necessarily indicative of future results.

Statement of Risk

The Instruments are not suitable for all investors, and trading in these Instruments is considered risky and is appropriate only for sophisticated investors and in particular any target market identified herein. These Instruments may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates, foreign exchange rates and other market conditions. Some Instruments may be physically settled or cash settled.

No liability

To the fullest extent permitted by law, neither we nor any of our directors, employees or agents is liable for any loss (including indirect, special or consequential losses or damages, and even if we have been advised of the possibility of loss) arising out of any person's use of, or reliance upon, the information contained herein.

Securities Act

Any Instruments that have not been registered under the United States Securities Act of 1933 may not be offered or sold in the United States except pursuant to an exception from the registration requirements of the Securities Act and applicable state securities laws and in such circumstances as may be permitted by applicable law.

No redistribution or reproduction

We specifically prohibit the redistribution or reproduction of this material in whole or in part without our prior written permission and we accept no liability whatsoever for the actions of third parties in this respect. © UBS 2020. All rights reserved.

Country-specific information

This material is distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services Licence No. 231087) and/or UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services Licence No. 231098). This materials contains general information and/or general advice only and do not constitute personal financial product advice. As such, the materials have been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting, consider the appropriateness of the materials, having regard to their objectives, financial situation and needs. Potential investors should obtain the relevant product offer document relating to the product referred to herein and consider and understand the product offer document before making any decision about whether to acquire such product.

UBS AG, Australia Branch is a foreign Authorised Deposit-Taking Institution ("foreign ADI") under the Banking Act 1959 (Cth), and is supervised by the Australian Prudential Regulation Authority. It is important for you to note that your investment is not a deposit product or other deposit liability and is not covered by the depositor protection provisions set out in Division 2 of the Banking Act 1959 (Cth).

In any event, provisions of the Banking Act 1959 (Cth) for the protection of depositors do not apply to foreign ADIs including UBS AG, Australia Branch. For example, depositors with foreign ADIs do not receive the benefit of the following protections:

- Deposits are not covered by the financial claims scheme and are not guaranteed by the Australian Government.
- Deposits do not receive priority ahead of amounts owed to other creditors. This means that if a foreign ADI was unable to meet its obligations or otherwise is in financial difficulties and ceases to make payments, its depositors in Australia would not receive priority for repayment of their deposits from the foreign ADI's assets in Australia.
- A foreign ADI is not required to hold assets in Australia to cover its deposit liabilities in Australia. This means that if the foreign ADI were unable to meet its obligations or otherwise is in financial difficulties and ceases to make payments, it is uncertain whether depositors would be able to access the full amount of their deposit.

UBS Securities Australia Ltd is a subsidiary of UBS AG. However, it is not an authorised deposit-taking institution under the Banking Act 1959 (Cth). The obligations of UBS Securities Australia Ltd do not represent deposits or other liabilities of UBS AG, and UBS AG does not stand behind, support or guarantee UBS Securities Australia Ltd in any way.